Next Article in Journal
A Multidisciplinary Approach to the Management of Eales Disease: A Case Report and Review of the Literature
Previous Article in Journal
Personalized Medicine Transformed: ChatGPT’s Contribution to Continuous Renal Replacement Therapy Alarm Management in Intensive Care Units
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Foss et al. The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. J. Pers. Med. 2022, 12, 692

by
Kimberly S. Foss
1,*,
Julianne M. O’Daniel
1,
Jonathan S. Berg
1,
Sabrina N. Powell
1,
Rosemary Jean Cadigan
2,
Kristine J. Kuczynski
2,
Laura V. Milko
1,
Katherine W. Saylor
3,
Megan Roberts
4,
Karen Weck
1,5 and
Gail E. Henderson
2
1
Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA
2
Department of Social Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
3
Department of Public Policy, University of North Carolina, Chapel Hill, NC 27599, USA
4
Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
5
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2024, 14(3), 234; https://doi.org/10.3390/jpm14030234
Submission received: 29 January 2024 / Accepted: 30 January 2024 / Published: 22 February 2024
(This article belongs to the Section Pharmacogenetics)

Text Correction

There was an error in the original publication [1] “The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation”.
In the original publication, the authors erroneously reported that the UCSF “Preventative Genomics Clinic” partnered with Color Health, Inc., but it did not.
A correction has been made to Section 3.4.
The paragraph “UCSF partnered with Color Health, Inc. to offer population health screening with institutional support, insurance billing, and available self-pay rates. The current Color Health, Inc. ‘Extended’ test offering includes 74 genes related to cancer, cardiovascular disease, and pharmacogenetics. Clinic providers counsel patients at risk for a hereditary condition based on their personal or family history and, if appropriate, offer screening for preventative health care and family planning. Approximately 40 patients were seen in 2020 for preventative health consultations” was replaced with “UCSF partnered with external clinical labs and their in-house CLIA-certified labs to offer proactive gene panels, pharmacogenetics testing, and carrier screening. Clinic providers counsel patients at risk for a hereditary condition based on their personal or family history and, if appropriate, offer screening for preventative healthcare and family planning. Approximately 40 patients were seen in 2020 for preventative health consultations.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Foss, K.S.; O’Daniel, J.M.; Berg, J.S.; Powell, S.N.; Cadigan, R.J.; Kuczynski, K.J.; Milko, L.V.; Saylor, K.W.; Roberts, M.; Weck, K.; et al. The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. J. Pers. Med. 2022, 12, 692. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Foss, K.S.; O’Daniel, J.M.; Berg, J.S.; Powell, S.N.; Cadigan, R.J.; Kuczynski, K.J.; Milko, L.V.; Saylor, K.W.; Roberts, M.; Weck, K.; et al. Correction: Foss et al. The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. J. Pers. Med. 2022, 12, 692. J. Pers. Med. 2024, 14, 234. https://doi.org/10.3390/jpm14030234

AMA Style

Foss KS, O’Daniel JM, Berg JS, Powell SN, Cadigan RJ, Kuczynski KJ, Milko LV, Saylor KW, Roberts M, Weck K, et al. Correction: Foss et al. The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. J. Pers. Med. 2022, 12, 692. Journal of Personalized Medicine. 2024; 14(3):234. https://doi.org/10.3390/jpm14030234

Chicago/Turabian Style

Foss, Kimberly S., Julianne M. O’Daniel, Jonathan S. Berg, Sabrina N. Powell, Rosemary Jean Cadigan, Kristine J. Kuczynski, Laura V. Milko, Katherine W. Saylor, Megan Roberts, Karen Weck, and et al. 2024. "Correction: Foss et al. The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. J. Pers. Med. 2022, 12, 692" Journal of Personalized Medicine 14, no. 3: 234. https://doi.org/10.3390/jpm14030234

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop